Neonatalintensive Care Unit, Women's and Children's Hospital Pingxiang, Jiangxi Province, China. Department of Neonatology, Jiangxi Maternal and Child Health Hospital Nanchang, Jiangxi Province, China. Department of Neonatology, Jiujiang City Maternal and Child Health Care Jiujiang, Jiangxi Province, China. Department of Neonatology, The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi Province, China.
American journal of translational research. 2021;13(4):2626-2634
OBJECTIVE To analyze the efficacy of hydroxyethyl starch (HES) combined with Ulinastatin (Uti) in the treatment of newborns with capillary leak syndrome (CLS). METHODS A total of 60 newborns with CLS admitted to four hospitals were selected as the study subjects, and were randomly divided into the control group (n = 30) and the observation group (n = 30) in
accordance with the random number table. The control group was treated with HES alone, while the observation group was treated with Uti combined with HES. RESULTS At 5 d after treatment, the incidence rates of systemic edema and pulmonary edema, the levels of CRP, NE, and BUN, and the duration for the improvement of systemic edema, pulmonary edema and NICU hospital stay in the control group were superior to those in the observation group, while the 24-h urine output, PaO(2) and MAP levels, the levels of A, SCr, ALT, and IL-10 in the observation group were superior to those in the control group (P < 0.05). After 3 months of follow-up after treatment, the mortality rate of newborns in the observation group (13.33%) was lower than that in the control group (36.67%) (P < 0.05). CONCLUSION HES combined with Uti can effectively alleviate edema, control inflammatory levels, and improve hepatic and renal functions and neonatal survival rate of newborns with CLS.
